Jan 13 (Reuters) - Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
Dealmakers are anticipating a surge in megadeals worth over $10 billion, buoyed by hopes of a more lenient antitrust environment under the incoming Trump administration.
The following is a list of deals that took place on Monday ahead of the JPMorgan Healthcare Conference:
GSK-IDRx
British drugmaker GSK GSK.L said that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx.
J&J-Intra-Cellular Therapies
Johnson & Johnson JNJ.N said it will buy Intra-Cellular Therapies ITCI.O for $14.6 billion, with plans to fund the deal through a combination of cash and debt.
Eli Lilly-Scorpion Therapeutics
Eli Lilly LLY.N plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments.
AbbVie-Simcere Pharmaceutical
AbbVie ABBV.N has obtained the option to license a new blood cancer drug candidate from Simcere Pharmaceutical's 2096.HK unit for markets outside China, in a deal valued at up to $1.06 billion.
(Reporting by Kamal Choudhury and Puyaan Singh in Bengaluru; Editing by Shailesh Kuber)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.